Bioxcel, Nektar and Merck KGaA in a Triple Collaboration for Pancreatic Cancer

Shots:

• The companies entered into a clinical collaboration for evaluating BioXcel’s BXCL701, Nektar’s NKTR-214 & Avelumab (co-developed and co-commercialized by Merck KGaA and Pfizer) as a triple combination therapy for pancreatic cancer

• In Nov,2017, BTI and Nektar Therapeutics initially collaborated for preclinical development and expand their collaboration on 24 Sept,2018 for novel triple combination therapy

• Under the collaboration, BTI will be responsible for the clinical development & Nektar will equally share development cost of novel triple combination therapy

Click here to read full press release/ article | Ref: Ascendis Pharma | Image: Warrior Trading News